Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash & Equivalents (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Cash & Equivalents for 10 consecutive years, with $48.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 36.27% year-over-year to $48.6 million, compared with a TTM value of $48.6 million through Sep 2025, down 36.27%, and an annual FY2024 reading of $52.9 million, down 30.71% over the prior year.
  • Cash & Equivalents was $48.6 million for Q3 2025 at Spero Therapeutics, up from $31.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $112.9 million in Q3 2021 and bottomed at $31.2 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $76.3 million, with a median of $76.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 32.13% in 2021, then plummeted 50.9% in 2025.
  • Year by year, Cash & Equivalents stood at $112.6 million in 2021, then fell by 3.09% to $109.1 million in 2022, then crashed by 30.04% to $76.3 million in 2023, then tumbled by 30.71% to $52.9 million in 2024, then dropped by 8.08% to $48.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for SPRO at $48.6 million in Q3 2025, $31.2 million in Q2 2025, and $52.9 million in Q4 2024.